London, United Kingdom
Biotecnol Limited, founded in 2014 and headquartered in the United Kingdom, is an innovative player in the Biotechnology, Health Care, and Pharmaceutical sectors. With the slogan "Immunotherapies for Life," the company leverages its proprietary Tribody™ and Trisoma® technologies to develop advanced immuno-oncology solutions.
In December 2018, the firm divested its initial immuno-oncology pipeline and technologies to Chiome, enabling them to focus on developing new immune-oncology products. A cornerstone of their innovation is the iChecks™ platform, designed to enhance tumor-specific T-cell activation while minimizing systemic toxicity, targeting heterogeneous and aggressive solid tumors.
Cancer Research UK's involvement as a shareholder since 2017 highlights the strategic alliances Biotecnol is fostering with leading cancer institutions. This partnership aligns with the company's objective to accelerate the development of cutting-edge therapies in the immune-oncology landscape.